Orthocell Posts $3.2M Quarterly Revenue, Up 7% from Prior Quarter
Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.
- Seventh consecutive quarter of record revenue at $3.2 million
- 7.0% revenue growth over previous quarter and 45.2% year-on-year increase
- US distributor network expanded to cover 25+ states and 40% of population
- Second Canadian distributor appointed, with sales targeted for March quarter
- Robust cash reserves of $49.4 million and expected $3 million R&D tax refund
Orthocell’s Sustained Growth Trajectory
Orthocell Limited (ASX – OCC), a regenerative medicine company specialising in nerve repair, has announced a record quarterly revenue of $3.2 million for the December 2025 quarter. This marks the seventh consecutive quarter of record revenue, reflecting a steady compound quarterly growth rate of 10.4% since Q3 FY24. The latest figures represent a 7.0% increase over the previous quarter and a substantial 45.2% rise compared to the same period last year.
Driving Forces Behind the Revenue Surge
The revenue growth is primarily attributed to increased sales of Orthocell’s flagship product, Remplir™, a nerve repair medical device. Strong market penetration in Australia continues to underpin the company’s performance, while initial sales in the United States have begun to contribute meaningfully. December saw approximately $90,000 in US Remplir sales, aligning with the company’s expectations and signalling early success in a highly competitive market.
Orthocell’s hybrid market entry strategy in the US, combining specialist distributors with internal field leadership, has proven effective. The company now boasts a distributor network spanning over 25 states, covering 40% of the US population. Progress with hospital Value Analysis Committees (VAC) is ahead of schedule, with 23 approvals secured out of 61 applications submitted. Additionally, Orthocell has conducted 11 major medical education meetings across key states, helping to introduce surgeons to Remplir’s clinical benefits and encouraging adoption.
Expanding Horizons – Canada and Beyond
Orthocell is also advancing its footprint in Canada, having recently appointed a second distributor. Initial sales from this region are targeted for the March quarter of FY26, with steady market adoption expected throughout the year. This expansion complements the company’s established presence in Australia, Singapore, New Zealand, and other markets, positioning Orthocell for broader international growth.
Financial Position and Outlook
With cash reserves of $49.4 million, including $7.4 million in cash and $42 million in term deposits, Orthocell is financially well-positioned to support its commercial expansion plans. The company also anticipates receiving a $3 million R&D tax incentive refund in the March quarter, which should further bolster its resources.
CEO and Managing Director Paul Anderson expressed optimism about the company’s trajectory, highlighting the successful US market entry and the potential for significant revenue growth as Remplir adoption accelerates. Orthocell’s approach to combining distributor networks with targeted medical education is laying a solid foundation for sustained growth in the sizeable US nerve repair market, estimated at US$1.6 billion.
Investors and observers will be keenly awaiting the full Quarterly Activity Report and Appendix 4C, due for release on 23 January 2026, for further insights into the company’s operational and financial progress.
Bottom Line?
Orthocell’s expanding US and Canadian presence, backed by strong cash reserves, sets the stage for a potentially transformative year ahead.
Questions in the middle?
- How quickly will Remplir sales scale across the broader US market beyond initial states?
- What impact will increased hospital approvals have on Orthocell’s revenue trajectory?
- How will competition in the nerve repair space affect Orthocell’s market share in 2026?
